‘Do you take any of this stuff, Howard?’ Trump roasts his cabinet about their weight while announcing blockbuster Medicare Ozempic deal

President Trump announced a deal with Eli Lilly and Novo Nordisk to expand access and reduce prices for popular GLP-1 obesity drugs like Zepbound and Wegovy. The agreement will extend Medicare coverage for obesity patients starting next year and implement phased price reductions for uninsured individuals via the TrumpRx program, targeting average prices as low as $245. Eli Lilly committed to selling Zepbound starter doses for $299 and other doses for up to $449, a $50 reduction, with new pill versions potentially costing $149/month. This initiative aims to significantly broaden market access for these lucrative treatments, addressing prior cost and coverage barriers, and is expected to impact sales volumes for the pharmaceutical manufacturers.

Analysis

President Trump's agreement with Eli Lilly and Novo Nordisk significantly expands market access for GLP-1 obesity drugs, Zepbound and Wegovy. Medicare coverage for obesity patients will begin next year, addressing a key barrier given over 100 million obese adults and prior limited coverage. Additionally, the TrumpRx program will phase in lower prices for uninsured patients, targeting an average of $245, a notable reduction from the current $500/month for higher doses.

Eli Lilly has committed to selling Zepbound starter doses for $299 and other doses up to $449, representing a $50 reduction from direct-to-patient prices. This initiative builds on Zepbound's already strong performance, with sales tripling to over $9 billion this year, and is expected to drive further volume growth for both Lilly (sentiment 0.8) and Novo Nordisk (sentiment 0.5), despite price concessions. The expedited FDA review for Lilly's orforglipron and upcoming decision for Novo Nordisk's Wegovy pill could further enhance market penetration.

This politically motivated move, aimed at addressing voter concerns over drug costs, signals a continued trend of government intervention in pharmaceutical pricing. While expanding access, the ultimate impact on consumer out-of-pocket costs remains variable due to insurance complexities. Investors should monitor the implementation of these pricing structures and the competitive landscape as new pill versions enter the market.

Key Decisions for Investors

• Monitor sales volumes and revenue impacts for Eli Lilly (LLY) and Novo Nordisk (NVO) as expanded Medicare coverage and new pricing structures take effect.
• Evaluate the long-term implications of increased government involvement in pharmaceutical pricing and potential precedents for other therapeutic areas.
• Assess competitive dynamics within the GLP-1 market, particularly with the expedited review of new pill formulations from Lilly and Novo Nordisk, which could intensify market share battles.